Education
About Us
Working with TipRanks
Follow Us
Michael Landsittel Insider Profile
4 Followers
Michael Landsittel, CFO at Blueprint Medicines, holds 72.92K shares in Blueprint Medicines (Ticker: BPMC). Most recently, Michael Landsittel Sold $5,284 shares of Blueprint Medicines on Mar 07, 2025 for an estimated value of 469.22K.
Profitable Transactions
3 out of 6 Profitable Transactions
Average Return
-24.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Michael Landsittel's holdings
Insider Roles
CFO
Roles that Michael Landsittel holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Mar 05, 2021 - Mar 05, 2022
Return:+40.50%
The most profitable trade made by Michael Landsittel
Michael Landsittel's Trading History
List of latest transactions for each holding click on a transaction to see Michael Landsittel's performance on stock
You May Also Like
Michael Landsittel insider profile FAQ
What is the percentage of profitable transactions made by Michael Landsittel?
The percentage of profitable transactions made by Michael Landsittel is 50%.
What is the average return per transaction made by Michael Landsittel?
The average return per transaction made by Michael Landsittel is -24.50%.
What stocks does Michael Landsittel hold?
Michael Landsittel holds: BPMC stocks.
What was Michael Landsittel’s latest transaction?
Michael Landsittel latest transaction was an Informative Sell of $469.22K.
What was Michael Landsittel's most profitable transaction?
Michael Landsittel’s most profitable transaction was an Informative Sell of BPMC stock on March 5, 2021. The return on the trade was 40.50%.
What is Michael Landsittel's role in Blueprint Medicines?
Michael Landsittel's role in Blueprint Medicines is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.